Prof. Dmitry Gabrilovich AstraZeneca, USA

Dmitry Gabrilovich, MD, Ph.D., is an Executive Director and Chief Scientist, Cancer Immunology, AstraZeneca. He studied dendritic cell (DC) biology at the Imperial College of London in the UK and then was trained in cancer research at U.T. Southwestern Medical School and Vanderbilt University. In mid-1990s his group demonstrated that... read moreDCs in cancer were functionally impaired. They have described the first tumor-derived factor directly implicated in DC defects in cancer and suggested that myeloid progenitor cells were the main targets for this negative effect. His group implicated lipid accumulation as one of the mechanisms negatively regulating the function of DCs in cancer. Dr. Gabrilovich made a major contribution to the discovery of cells that are now called myeloid-derived suppressor cells (MDSC). His group characterized these cells, described a number of molecular mechanisms regulating expansion and function of these cells. His group provided first evidence that MDSC can be therapeutically targeted in patients. Before joining AstraZeneca Dr. Gabrilovich was Robert Rothman Endowed Chair in Cancer Research and Head, Section of Dendritic Cell Biology at H. Lee Moffitt Cancer Center and then Christopher M. Davis Professor in Cancer Research at the Wistar Institute in Philadelphia and Wistar Professor at the Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania. Dr. Gabrilovich is American Cancer Society Research Professor and during the last 9 years is listed as one of the most highly cited researchers in the field of Immunology.